Anastrozole vs CJC-1295 (without DAC)
FDA Approved vs Well Studied
synergistic Mechanism-based · 60% CJC-1295 (without DAC) helps manage estrogen conversion from Anastrozole. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Anastrozole CJC-1295 (without DAC)
Weight 293.37 Da 3,367.97 Da
Half-life ~40-50 hours 30 minutes - 2 hours
Chain — 30 amino acids
Type Nonsteroidal aromatase inhibitor (triazole derivative) GHRH analog
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Dosing Protocols
Anastrozole
0.25-0.5mg EOD or E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Research Evidence
Anastrozole CJC-1295 (without DAC)
Status FDA Approved Well Studied
References 5 studies 5 studies
Latest — November 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.